Vaxon Biotech Overview

  • Status
  • Out of Business
  • Employees
  • 6
  • Latest Deal Type
  • Out of Business

Vaxon Biotech General Information


Developer of therapeutic vaccines designed to offer treatment for cancer. The company's vaccines are developed to treat lung, gastric, prostate, breast, renal, liver and colorectal cancers by stimulating the immune system to recognize and attack human cancer cells without harming normal cells, enabling patients to get treated from cancer and enjoy a healthy life.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Therapeutic Devices
Primary Office
  • Tour CIT, BP 191
  • 3 rue de l'Arrivée
  • 75749 Paris
  • France
+33 01 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxon Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jan-2020 Completed Out of Business
3. Early Stage VC 01-Jan-2011 Completed Generating Revenue
2. Seed Round 01-Apr-2004 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2003 Completed Startup
To view Vaxon Biotech’s complete valuation and funding history, request access »

Vaxon Biotech Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial